BioGecko

Vol 12 Issue 03 2023

ISSN NO: 2230-5807

m-RNA: Recent Trends in Vaccinology

Poonam P. Patil[1*], Ashish V. Dashpute[2], Dr.Sunil.J.Aher[3], Supriya S. Bhagwat[4], Yogiraj Gadhave[5], Dr. Kiran C. Mahajan[6]

1. Assistant Professor and HOD, Department of Pharmaceutical Chemistry, Sanjivani College of Pharmaceutical Science & Research, Kopargoan,Maharashtra, India-423601
2. PG Scholar, Department of Quality assurance, Sanjivani College of Pharmaceutical Science & Research, Kopargoan, Maharashtra, India-423601
3. Associate Professor, Department of Pharmaceutics, Sanjivani College of Pharmaceutical Science & Research, Kopargoan,Maharashtra, India-423601
4.Assistant Professor, Department of Pharmaceutics, Sanjivani College of Pharmaceutical Science & Research, Kopargoan,Maharashtra, India-423601
5. PG Scholar, Department of Quality assurance, Sanjivani College of Pharmaceutical Science & Research, Kopargoan,Maharashtra, India-423601
6. Associate Professor, Department of Pharmaceutics, Sharadchandra Pawar College of Pharmacy, Pune, Maharashtra, India-412409.

(Corresponding Author: Poonam.P.Patil[1]*,

ABSTRACT:
mRNA vaccine synthesis starts with preparation of plasmid p-DNA preparation of adulteration free p-DNA is important to create a mRNA vaccine that can induce strong immune response. The efficiency of mRNA vaccine generally depends of the amount of mRNA Bing translated to produce antigen. The concentration of antigens in blood is also affected by the presence of proteolytic enzyme in blood. Generally, the proteolytic enzyme inactivates the antigens there by reducing the efficiency of mRNA vaccine. Self-amplifying mRNA vaccine are vaccines that has additional code for preparing replica of them self-there by enhancing the translation of mRNA. Among various problems with mRNA vaccine the delivery of mRNA vaccine is most important one the mRNA vaccine delivered directly or naked mRNA vaccine show less effectiveness compared to the cationic lipid polymer based delivered mRNA vaccines. The use of LNPs for delivery of mRNA vaccine has shown some great results and promises to be the future of mRNA vaccine delivery. mRNA vaccine induces various types of immune response the antigen mediated immune response are most common and effective one.

Keywords: - mRNA, DNA, RNA, Protein, Enzyme, Immunization, Vaccination

1.INTRODUCTION:

Vaccination saves countless of lives every year. Due to vaccination, the pseudovariola infection has seen very rarely now and the infections of polio, rubeola and other illnesses has been radically reduced around the golbe. Ordinary like live weakened and inactivated microorganisms and subunit antigen and give strong immune response against diseases. Because of the chances of contamination with live microorganism. In addition, for most arising new infection or pandemic the convectional vaccines Bing time consuming to manufacture are not mass producible when the need arises, the fundamental requirement for more fast vaccine production is required. At last, ordinary vaccination approaches may not be effective in treatment of diseases like malignant growth. The advancement of more powerful and flexible immunization stages is in this manner critically required. plasmid DNA vaccination with A viral delivered Deoxyribonucleic acid gets rid of disease and vaccination with live microorganisms produces intense responses . Moreover, Aviral delivered Deoxyribonucleic acid

vaccination Development is effective and efficient, without the chances of contamination with live organism and suitable for large scale manufacturing.
For antigen interpretation Deoxyribonucleic acid Vaccines and mRNA vaccines have different ways for antigen expression DNA needs to cross the plasma membrane and then transcribed into RNA and again travel into cytosol to get translated into desired proteins (Antigens).DNA vaccines have shown less efficacy in early clinical trials though considered safe over RNA vaccines, but possibility of integration of exogenous DNA with host DNA cannot be denied with may cause carcinogenicity. As the new research in vaccinology comes, mRNA vaccines are a promising candidate for the future of vaccination regardless.

1.1. mRNA SYNTHESIS:
Practical in vitro synthesis of Complementary DNA (c DNA) is obtained by the encryption of a Complementary DNA strand. ordinarily plasmid Deoxyribonucleic acid (pDNA) is utilized utilising RNA polymerase from a bacteriophage. Thus Synthesis of plamid Deoxyribonucleic acid is the most important phase for development of massenger RNA. massenger RNA production appears to require more work than assembling of p Deoxyribonucleic acid. Unprocessed pDeoxyribonucleic acid contains fragments of bacterial DNA.(Kaslow 2004) There three types of pDNA (supercoiled, loosened up circle or straight) are present invariable extents. Subsequently, the extraction of unadulterated and pure pDNA is must for the production of vaccine.(Liu 2010) fractions of vector DNA and It's not concerning that pDNA is heterogeneous, then again, whenever linearized pDNA is translated utilizing RNA polymerase.(Kaslow 2004) The same is true for pDNA layouts for in vitro synthesis, which primarily consist of a bacteriophage promoter on an ORF, an alternative poly[d(A/T) succession translated into poly(A), and a novel limitation site for linearization of the plasmid to ensure characterised transcription end (the cap is not encoded by the template).(2004) Kaslow Recombinant RNA polymerase is used in a combination to convert the linearized pDNA template into mRNA. (T7, T3 or SP6) and nucleoside triphosphates.(Probst et al. 2007) Capped mRNA can be obtained via transcription. In order to recall the reaction, a cap simple as the dinucleotidem7G(5')-ppp-(5')G (referred to as "cap 0" in the following) may be used. Translation begins with the cap 0 rather than GTP if the cap 0 is abundant in GTP, resulting in coated mRNA.n.d. (Pascolo) However, the cap could have been enzymatically inserted after translation. If the pDNA format doesn't provide a poly(A) tail, one can also be inserted after translation. After translation, DNase breaks down the pDNA format and damaged bacterial DNA.2007 (Probst et al.).
Intriguingly, Woff et al. predicted that mRNA vaccines were feasible for direct quality exchange. Both conventional mRNA vaccines and self-improving mRNA vaccines, which are obtained from positive sequence RNA infections, are the two forms of mRNA antibodies that have been developed to date. Despite the fact that mRNA-based vaccines were originally tested in the middle of the 1990s, they were initially not extensively employed due to concerns about their fragile nature caused by ribonucleases and their restricted production capabilities. Ross and collaborators released an introductory exhibit in 1995 showing how simplifying and detailing might increase mRNA reliability. Since then, efforts to develop mRNA vaccines have exploded, and mRNA is now possible to generate artificially using an enzyme reaction that does not require the presence of cells. The transcribing in a dish



Fig.1. mRNA Synthesis & Purification

1.2. mRNA VACCINE PHARMACOLOGY:

mRNA serves as an intermediate for production of proteins by translation. Two significant kinds of RNA are as of now concentrated as vaccines non-amplifying mRNA self-amplifying RNA. Ordinary mRNA-based vaccines encode the antigen of interest and contain 5′ and 3′ untranslated areas (UTRs), though self-intensifying RNAs contains information for the synthesis of antigen as well as the viral replication apparatus that empowers intracellular RNA replicate and produce more proteins.(Schenborn and Mierendorf 1985)

The development of ideally interpreted invetrotranscribed mRNA appropriate for medicinal use has been explored previously.(Konarska, Padgett, and Sharp 1984)(Munroet and Jacobson 1990) Momentarily, mRNA is created from a direct format utilizing a polymerase (Gong et al. 2006). The mRNA is hence designed to look like completely mature RNA particles as they happen normally in the protoplast of eukaryotic cells.(Pascolo 2004)

Additionally, there has recently been interest in mRNA complexing for in vivo administration.(Kaslow 2004)(Acids 1984) Exposed mRNA is immediately deactivated by extracellular RNases(Konarska et al. 1984) and extracellular RNases isn't between analysed effectively. Consequently, an extraordinary assortment of in vitro and in vivo interfering has been fostered that work with cell absorption ofmRNA and shield it fromdeactivation. When the mRNA travels to the protoplasm, the cell tra produces protein that goes through cellular changes, bringing about acomplete practical protein. The component of massenger RNA is especially favourable for immunizations and amino acid substitution treatments that require protoplasmic proteins to be given to the right cell compartments for legitimate presentation or capability. IVT mRNA is at long last corrupted by normal physiological cycles, consequently lessening the risk of metabolite harmfulness.
mRNAvaccinations are productive at antigen formation, yet succession and absence optional deliverysystem can restrain protein interpretation. On account in RNA science getting it, a few techniques can be utilized to build the strength of mRNAvaccination , At present, most vaccines being used, except for a few vaccination, should be shipped and put away in a continuous cold-chain process, which is inclined failureparticularly in developing country, areas of countries with most population living in forest these necessities are not being met by accessible successful vaccination to forestall and eradicate irresistible sicknesses. Thusly, the advancement of vaccines that can survive at higher temperatures has been acquiring attention. Enhancementin plan of manufactured mRNAimmunizations have shown that creating thermostable vaccines is a achievable. The outcomes portrayed by Jones showed that lyophilised mRNA is steady for no less than year at four degree Celsius.Subsequent to being translated, these mRNAs showed highlevels of given profoundly viable and durable resistance in infant and old animal models. One more frerezed dried mRNA immunization was demonstrated to be steady at 5-25◦C for a year and 40◦C for a 1/2 year.(Ogg and Wickens 1990)furthermore study showed that when a protamine-containing traditional mRNA-based rabies vaccines was exposed to wavering temperatures somewhere in the range of 4 and 56◦C for 20 cycles and openness 70◦C, its immunogenicity and defensive impacts were not compromised.



Fig.2. mRNA Delivery & Expression

1.3. ENHANCEMENT IN mRNA INTERPRETATION :

This topic has been extensively discussed in previous reviews.ws(Konarska et al. 1984)(Munroet and Jacobson 1990) accordingly, we momentarily sum up the key discoveries . The 5′ and 3′ UTR components arrangement significantly impact security and interpretation of mRNA, the both of them are basic worries in mRNA vaccination. The delivery system that protect mRNA like mammelian qualities and incredibly enhances life and efficacy in helpful mRNAs(Ogg and Wickens

1990)(Munroet and Jacobson 1990)A 5′ cap expected for effectiveness of antigen creation from mRNA.(Munroet and Jacobson 1990) Different variants in 5′ covers incorporated during or after the translation response utilizing a vaccine infection capping enzyme(Anon 1982) or consolidating engineered covering.(Chetverin 2004)(Probst et al. 2007)The poly adinine tail likewise has a important part in mRNA interpretation and durability.(Pascolo n.d.) subsequently, an ideal length of poly(A)tail(Liu 2010)either directly from the encoding DNA format or by using poly(A) polymerase, should be added to the mRNA. Protein interpretation is also impacted by codon use.(Probst et al. 2007). Supplanting uncommon codons with habitually utilized equivalent codons have plentiful tRNA in the protoplasm is typical to increment antigen creation from mRNA, albeit precision of this research is not tested. Advancement of G:C content is one more type of grouping enhancement that has been displayed to increment consistent state mRNA levels in vitro and protein present in vivo.



Fig.3. non-amplifying mRNA Purification

1.4. PROGRESS IN mRNA VACCINE DELIVERY SYSTEM:

Productive in vivo mRNA delivery is basic to accomplishing helpful in mRNA vaccines better performance. Exogenous mRNA should overcome the resistance of the lipid film to arrive at the protoplasm to be converted into antigen.(((Konarska et al. 1984)Cell administration and organ distribution can be strongly impacted by mRNA take-up by the cell and its physicochemical characteristics. Currently known methods for delivering mRNA vaccines may be divided into two categories. First, mRNA is packed into lipid nanoparticles, followed by the transfected cells(((Arnaud-Barbe et al. 1998)and second, direct parenteral infusion of mRNA regardless of a transporter.(((Acids 1980)Lipid nanoparticle stacking permits exact control of the cell target, translation effectiveness and other cell conditions, yet as a type of cell treatment, it is a costly and work in a faster way to deal with immunization. Direct injection of mRNA is relatively fast and practical, yet it doesn't yet permit exact and productive cell-type-explicit delivery, despite the fact that there has been ongoing advancement in this regard(((Sorrentino and Organica 1998) Both of these methodologies have been investigated in different structures The kind and amount of antigen articulation as well as the potency of the safe reaction are determined by the organisation strategy and definition of mRNA vaccines. Intravenous organisation of unmodified exposed mRNA, for example,

resulted in rapid ribonuclease absorption and the sensation of the normal invulnerable reaction, but these obstacles can be circumvented by appropriate delivery frameworks and mRNA changes..((((Munroet and Jacobson 1990)In light of a restriction on the generation of antigen, mRNAvaccines are regulated using a fundamental or close technique. The primary delivery routes for mRNA immunisations against irresistible diseases are direct intramuscular (i.m), intradermal (i.d.), or subcutaneous infusion of invitrodeciphered mRNA.

Intravenous (i.v.) systems are used when the fundamental production of important antigens is necessary, typically for restorative purposes. The manner that many antigens can function with great efficiency and cause significant humoral and cellular responses following mRNA immunisation has been the subject of numerous publications that have recently been widely disseminated. The effect of course of organisation on the energy of antigen articulation has been studied using lipid nanoparticles (LNP) layered with nucleoside altered regular mRNA expressing firefly luciferase.

1.5. INFUSION OF NAKED mRNA IN VIVO:

Naked mRNA has been utilized effectively for in vivo vaccinations, particularly in designs that specially target antigen-introducing cells, as in intradermal(((Pascolo n.d.)(((Anon 1982) and intranodal injections. (((Anon 1982)((((((Probst et al. 2007)A new report showed that intranodal vaccinations with exposed, unmodified mRNA encoding cancer related neoantigens created hearty Lymphocyte reactions and enhanced the immune response against the cancer cells. Direct delivery into the lymphnode protects the antigen form proteolytic enzymes present in the blood thereby increasing efficacy.

1.6. ADVANCE DELIVERY TECHNIQUES:

To expand the efficiency of mRNA take-up in vivo, actual strategies have been utilized to enter the cell wall. An early report showed that mRNA complexed with gold particles could be communicated in tissues utilizing a quality carrier, a microprojectile method.(((((Fotin-Mleczek et al. 2011) The quality was demonstrated to be an effective RNA delivery and vaccination strategy in mouse models(((Chetverin 2004)however no viability information large animals or people are accessible. In vivo electroporation has likewise been utilized to expand delivery of remedial RNA(((Liu 2010)(((Anon 1982)in any case, in one review, electroporation expanded the immunogenicity of just a self-amplifying RNA and not a non-amplifyingmRNA-based vaccine.(((Liu 2010) Actual techniques can be restricted by expanded cell passing and confined admittance to target cells or tissues. As of late, the field has rather preferred the utilization of lipid or polymer-based nanoparticles as strong and adaptable delivery vehicles.

1.7. CATIONIC LIPID AND POLYMER-BASED DELIVERY:

Highly effective mRNA translation occurs in the presence of cationic lipids or polymers, such as Transport mRNA (Mirus Bio LLC) or Lipofectamine (Invitrogen), which are readily available, affordable, and perform admirably in a variety of crucial cells and disease cell lines,(((((Fotin-Mleczek et al. 2011)(((Ogg and Wickens 1990) yet, they typically exhibit low in vivo survivability or high levels of poisonousness (N.P. what's more, D.W., unpublished perceptions). Extraordinary efforts have been made to generate complexing reagents that are appropriately designed for safe and effective usage in vivo. These efforts are discussed in-depth in a few recent reviews.(((Kaslow 2004)(((Acids 1984)In the past several years, cationic lipids and polymers have increasingly been used as organising agents for mRNA. The siRNA technology, which has been used for 10 years, has generated significant attention that has clearly benefited the mRNA sector. Lipid nanoparticles (LNPs) have emerged as one of the most interesting and popular mRNAdelivery tools. An ionizable cationic lipid, which promotes self-aggregation into infection-sized (100 nm) particles and enables endosomal delivery of mRNA to the cytoplasm, lipid-connected polyethylene glycol, which extends the half-life of specific cholesterol, a balancing out specialist, and naturally occurring phospholipids, which support lipid bilayer structure, are the other two components that are frequently found in LNPs. Numerous studies have demonstrated effective in vivo siRNA delivery using LNPs,(((Arnaud-Barbe

et al. 1998) However, it has recently been demonstrated that LNPs are effective tools for in vivo distribution of standard, non-repeating mRNA and self-amplifying RNA .(((Acids 1980) According to Robert and Felgner (1989), fundamentally delivered mRNA-LNP structures primarily target the liver due to the restriction of apolipoprotein E and the subsequent receptor-interceded uptake by hepatocytes. Additionally, intradermal, intramuscular, and subcutaneous system have been shown to produce drawn-out protein articulation at the injection site.(Organica and Sorrentino, 1998)(1989, Robert and Felgner) Both for fake liposomes and for naturally occurring exosomes, the components of mRNA escape into the cytoplasm are inadequately sensed.2007 (Probst et al.) The field of RNAdelivery will most likely greatly benefit from further research in this area.

1.8. MECHANISM OF ANTIBODY REACTION INDUCED BY mRNA VACCINES:

The insusceptible reaction bymRNA still needs to be explained. The course of mRNA antibody acknowledgment by cell receptors and the system of receptors initiation are as yet not satisfactory. Endosomal toll-like receptors (TLRs) and the Mechanism I-like protein family have been identified as two different types of RNA receptors that function intracellularly. TLR-3, TLR7, TLR8, and TLR9, that are only found in the enzymatic compartment of cells such DCs, macrophages, and monocytes, are divided into the preceding group. TLR3 detects double-stranded RNA (dsRNA) longer than 45 base pairs as well as dsRNA produced as a result of single-strand RNA (ss-RNA) forming optional designs or obtained from intermediates of viral replication. messenger RNAs rich in polyuridines, guanosines, and uridines activate TLR7 and TLR8. While TLR8 only detects single stranded RNA (ss-RNA), TLR7 may connect both dsRNA and ssRNA.(Organica and Sorrentino, 1998) TLR7 activation can enhance antigen display, promote cytokine release, and stimulate B cell responses..The final family includes Apparatus I, MDA5, and LGP2 and serves as an example of an acknowledgement receptor (PRR).RIG-I stimulates the production of IFN by specifically detecting ss-RNA and dsRNA carrying a 5′ triphosphate.The simple elaborate IFNinduction via Apparatus Inactivation beg layout in viral genomic segments. Another cytosolic RNA sensor, MDA5, can recognise designed RNA, such as poly I:C and long dsRNA created during RNA infection replication. Recognition by dsRNA triggers the activation of IRF3 and the nuclear factor k which in turn triggers increased production of type I Interferon. The elements of dsRNA detected by the PRR sensors can occasionally function as an adjuvant by using IFN. TLR3, 7, 8, Apparatus I, and MDA5 are a few of the inherent resistance mechanisms that mRNA immunisations can activate.The kind of in vitro translated mRNA, delivery medium, determines IFN uptake by mRNA antibodies through RNA sensors. The natural resistive framework's ability to recognise mRNA acts as a double-edged sword at the point where assaulting particles converge. Regular exogenous mRNA stimulates the creation of potent flaming cytokines and type I INFs, which stimulate T and B type replies but may be harmful to the development of antigens. Partners described a method for measuring PRR enactment by IVT mRNA in individual cells and tissue segments. In this method, nearness ligation testing (PLAs) was used to activate solid immune responses that are responsive to TLR7 signalling after intradermal injection of the RNactive antibody invention from CureVac AG. Chemokines are upregulated in response to TLR7 activation, which selects intrinsically resistant cells.

monocytes and DCs to the injection site. At the infusion site, provocation cytokines including TNF- and IL-6 that are known to increase the recruitment of resistant cells have been active. However, the activation of PRRs may be impeding if antigen articulation is prematurely shut down following mRNA immunisation. In IFN 1/2 animals or by co-organization of IFN antagonist, reliably antigen articulation, humoral and lymphocyte replies to mRNA immunisation, both from conventional and amplifyingmRNA, were all enhanced.

The negative effects of excessive IFN activation might occur at the level of lymphocytes as well as delaying RNA enhancement in the case of self-intensifying RNA immunisations and articulation. While type I IFN can control how antigen-prepared CD8+ lymphocytes become cytotoxic effectors, they can also hasten the depletion of white blood cells.The time and intensity of type I IFN elicited might determine whether type I Interferon represses or activates the CD8 immune-mediated microorganism response to mRNA antibodies

If the activation of type I IFN receptors occurs before the activation of white blood cell receptors, lymphocyte restraint may prevail. Reduced invulnerable enactment and increased antigen production are possible with modified mRNA treated with pseudouridines and cleaned with HPLC. In one instance, i.p. infusion of mRNA encoding pseudouridines triggered antigen articulation in mice without the use of cytokines. Additionally, it has been demonstrated in a few distributions that the purity and delivery methods affect the immune response boosted by mRNA vaccines. Stranger still, a recent study revealed that altered mRNA typed into LNPs has an adjuvant effect, activates a large number of germinal centre B cells with long-lasting, high-liking killer antibodies, and causes a significant T follicular partner reaction.

1.9. THERAPEUTIC VACCINES mRNA:

Therapeutic mRNA vaccines are a type of vaccine that is designed to treat diseases rather than prevent them. Unlike traditional vaccines that work by preventing an infection before it occurs, therapeutic mRNA vaccines aim to stimulate the body's immune system to attack an existing disease, such as cancer.(Anderson et al. 2011)

The process for developing therapeutic mRNA vaccines involves creating mRNA sequences that encode for specific proteins or antigens that are present on the surface of cancer cells or other diseased cells.(Anon 1998) These mRNA sequences are then delivered into the patient's body, where they instruct the body's cells to produce the targeted antigens. The body's immune system then recognizes these antigens as foreign and mounts an attack against them, which can lead to the destruction of the diseased cells.(Anon 1998)

One of the advantages of therapeutic mRNA vaccines is that they can be customized to target specific antigens that are unique to a particular disease or individual.(Granstein, Ding, and Ozawa 2000) This means that they have the potential to be highly effective and have fewer side effects than traditional treatments like chemotherapy or radiation.(Anderson et al. 2011)

Several companies, including Moderna and BioNTech, are currently developing therapeutic mRNA vaccines for cancer treatment.(Anderson et al. 2011)These vaccines are still in the early stages of development, but early clinical trials have shown promising results in terms of safety and efficacy. If successful, therapeutic mRNA vaccines could offer a new, more targeted approach to cancer treatment, and could potentially be used to treat other diseases as well.(Anon 1998)

1.10.COMBINATION mRNA VACCINE:

Combination mRNA vaccines are a type of vaccine that combines multiple antigens or targets into a single vaccine. These vaccines are designed to provide protection against multiple diseases or strains of a disease with a single injection.(Anon 1998)

The development of combination mRNA vaccines is an active area of research, and several companies, including Moderna and CureVac, are working on developing these vaccines. One potential application of combination mRNA vaccines is in the development of a single vaccine that provides protection against both the flu and COVID-19.(Granstein et al. 2000)

The advantage of combination mRNA vaccines is that they can potentially reduce the number of injections that a patient needs to receive to achieve full protection against multiple diseases.(Granstein et al. 2000)Additionally, combining multiple antigens into a single vaccine can also help to improve the immune response to each antigen, leading to a more effective vaccine overall.(Granstein et al. 2000)

However, developing combination mRNA vaccines can also be challenging. For example, different antigens may require different delivery methods or formulations, and combining multiple antigens into a single vaccine may also increase the risk of adverse reactions or side effects.(Anderson et al. 2011)

Despite these challenges, the development of combination mRNA vaccines is an area of active research, and there is significant interest in developing vaccines that can provide protection against multiple diseases with a single injection.(Anderson et al. 2011)

REFERENCE: -

Acids, Nucleic. 1984. "Functional Messenger RNAs Are Produced by SP6 in Vitro Transcription of Cloned cDNAs." 12(18):7057–70.
Acids, Ribonucleic. 1980. "5 â€™ -Terminal Cap Structure in Eucaryotic Messenger Ribonucleic Acids." 44(2):175–205.
Anderson, Bart R., Hiromi Muramatsu, Babal K. Jha, Robert H. Silverman, Drew Weissman, and Katalin Karikó. 2011. "Nucleoside Modifications in RNA Limit Activation of 2′-5′- Oligoadenylate Synthetase and Increase Resistance to Cleavage by RNase L." *Nucleic Acids Research* 39(21):9329–38. doi: 10.1093/nar/gkr586.
Anon. 1982. "RNA Sex." (1):1148–50. doi: 10.1016/j.chembiol.2003.12.003.
Anon. 1998. "© 1998 Nature Publishing Group Http://www.nature.com/naturebiotechnology."
Arnaud-Barbe, Nadège, Valérie Cheynet-Sauvion, Guy Oriol, Bernard Mandrand, and François Mallet. 1998. "Transcription of RNA Templates by T7 RNA Polymerase." *Nucleic Acids Research* 26(15):3550–54. doi: 10.1093/nar/26.15.3550.
Chetverin, Alexander B. 2004. "Replicable and Recombinogenic RNAs." *FEBS Letters* 567(1):35–41. doi: 10.1016/j.febslet.2004.03.066.
Fotin-Mleczek, Mariola, Katharina M. Duchardt, Christina Lorenz, Regina Pfeiffer, Sanja Ojkić-Zrna, Jochen Probst, and Karl Josef Kallen. 2011. "Messenger RNA-Based Vaccines with Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity." *Journal of Immunotherapy* 34(1):1–15. doi: 10.1097/CJI.0b013e3181f7dbe8.
Gong, Peng, Craig T. Martin, Peng Gong, and Craig T. Martin. 2006. "By T7 RNA Polymerase *." 23533–44. doi: 10.1074/jbc.M604023200.
Granstein, Richard D., Wanhong Ding, and Hiroaki Ozawa. 2000. "Induction of Anti-Tumor Immunity with Epidermal Cells Pulsed with Tumor- Derived RNA or Intradermal Administration of RNA." *Journal of Investigative Dermatology* 114(4):632–36. doi: 10.1046/j.1523-1747.2000.00929.x.
Kaslow, David C. 2004. "A Potential Disruptive Technology in Vaccine Development: Gene-Based Vaccines and Their Application to Infectious Diseases." *Transactions of the Royal Society of Tropical Medicine and Hygiene* 98(10):593–601. doi: 10.1016/j.trstmh.2004.03.007.
Konarska, Maria M., Richard A. Padgett, and Phillip A. Sharp. 1984. "Recognition of Cap Structure In Vitro of mRNA Precursors." 38(October 1954):731–36.
Liu, Margaret A. 2010. "Immunologic Basis of Vaccine Vectors." *Immunity* 33(4):504–15. doi: 10.1016/j.immuni.2010.10.004.
Munroet, David, and Allan Jacobson. 1990. "mRNA Poly(A) Tail,." 10(7):3441–55.
Ogg, S., and M. Wickens. 1990. "I O . + .I." 277–81.
Pascolo, Steve. 2004. "Messenger RNA-Based Vaccines." 1285–94.
Pascolo, Steve. n.d. "Vaccination With Messenger RNA." 127:23–40.
Probst, J., B. Weide, B. Scheel, B. J. Pichler, I. Hoerr, H. G. Rammensee, and S. Pascolo. 2007. "Spontaneous Cellular Uptake of Exogenous Messenger RNA in Vivo Is Nucleic Acid-Specific, Saturable and Ion Dependent." *Gene Therapy* 14(15):1175–80. doi: 10.1038/sj.gt.3302964.
Robert, W., and Philip L. Felgner. 1989. "Cationic Liposome-Mediated RNA Transfection." 86(August):6077–81.
Schenborn, Elaine T., and Robert C. Mierendorf. 1985. "Nucleic Acids Research." 13(17):6223–36.
Sorrentino, S., and ChimicaOrganica. 1998. "Human Extracellular Ribonucleases : Multiplicity , Molecular Diversity and Catalytic Properties of the Major RNase Types." 54:785–94.